Therapy Class Overview : Rituximab Biosimilar:Life Sciences Market Research Reports

Life Sciences Market Research Reports

The Ultimate Sports Fundraising Program This $27 online course teaches fundraising approaches specifically for sports programs. Learn to raise money like the nation's top programs. Sign up today. From our sponsors

Therapy Class Overview : Rituximab Biosimilar Oct 7th 2013, 00:00, by rnrmahesh Approval of Inflectra/Remsima,  the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson’s Remicade, which is approved for RA, Crohn’s disease and several other conditions and had $2 billion in sales in Europe last year.  This approval has further increase the optimism of companies developing and marketing biosimilars and the wait for the launch of others in queue Rituxan, Herecptin, Enbrel etc may not be too long. These three drugs alone had worldwide sales of ~$21b in 2012. Commercial success of biosimilars will be … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=119083. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/therapy-class-overview-rituximab-biosimilar-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions